REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3‐4) FLUDARABINE/BUSULFAN‐BASED CONDITIONING REGIMENS FOR NON‐HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS. (June 2017)

• Record Type: Journal Article
• Authors: Le Bourgeois, A.; Labopin, M.; Blaise, D.; Ceballos, P.; Vigouroux, S.; Peffault De Latour, R.; Suarez, F.; Bulabois, C.; Bay, J.; Chantepie, S.; Deconinck, E.; Daguindau, E.; Contentin, N.; Yakoub‐Agha, I.; Cornillon, J.; Francois, S.; Turlure, P.; Charbonnier, A.; Rohrlich, P.; N'Guyen, S.; Maillard, N.; Marchand, T.; Mohty, M.; Chevalllier, P.
• Is Part Of: Hematological oncology. Volume 35(2017)Supplement 2
• Page Start: 193
• Page End: 194
• Publication Date: 2017-06
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2438_55
• Languages: English
• ISSNs: 0278-0232